Data / Drug companies / beta Lactamase Inhibitor
beta Lactamase Inhibitor drugs: 17 drugs from 63 companies in the FDA NDC directory
beta Lactamase Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 335 products in this class from 63 companies, covering 17 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on September 21, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 63Companies
- 335Products
- 17Drugs by generic name
Drugs in the beta Lactamase Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Amoxicillin and clavulanate potassium | 203 | 35 |
| Piperacillin and tazobactam | 47 | 13 |
| Ampicillin sodium and sulbactam sodium | 24 | 7 |
| Piperacillin sodium and tazobactam sodium | 21 | 5 |
| Ampicillin and sulbactam | 13 | 4 |
| Piperacillin sodium,tazobactam sodium | 9 | 2 |
| Ampicillin sodium, sulbactam sodium | 4 | 2 |
| Piperacillin and tazobactam and sodium chloride | 3 | 1 |
| Tazobactam sodium and piperacillin sodium | 3 | 1 |
| Amoxicillin/clav pot | 1 | 1 |
| Amoxicillin/clav pot oral susp | 1 | 1 |
| Aztreonam and avibactam | 1 | 1 |
| Ceftazidime, avibactam | 1 | 1 |
| Ceftolozane and tazobactam | 1 | 1 |
| Imipenem anhydrous, cilastatin, and relebactam anhydrous | 1 | 1 |
| Meropenem-vaborbactam | 1 | 1 |
| Piperacillin sodium, tazobactam sodium | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| NuCare Pharmaceuticals,Inc. | 31 | tablet, film coated; powder, for suspension | Generic drugs (ANDA) | September 19, 2022 |
| A-S Medication Solutions | 17 | powder, for suspension; tablet, film coated | Generic drugs (ANDA) | November 21, 2022 |
| Eugia US LLC | 16 | injection, powder, for solution; injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 12, 2023 |
| Fresenius Kabi USA, LLC | 15 | injection, powder, for solution; injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 18, 2018 |
| Preferred Pharmaceuticals Inc. | 13 | tablet, film coated; powder, for suspension | Generic drugs (ANDA) | July 31, 2026 |
| Sandoz Inc | 12 | injection, powder, lyophilized, for solution; tablet, film coated | Generic drugs (ANDA) | October 25, 2021 |
| Remedyrepack Inc. | 10 | tablet, film coated; tablet | Generic drugs (ANDA) | September 21, 2026 |
| Asclemed USA, Inc. | 9 | tablet, film coated; powder, for suspension | Generic drugs (ANDA) | May 1, 2020 |
| Proficient Rx LP | 9 | tablet, film coated; powder, for suspension | Generic drugs (ANDA) | January 20, 2012 |
| PD-Rx Pharmaceuticals, Inc. | 8 | tablet, film coated; tablet | Generic drugs (ANDA) | August 23, 2016 |
| Sportpharm LLC | 8 | tablet, film coated; tablet, multilayer, extended release | Generic drugs (ANDA) | August 12, 2019 |
| WG Critical Care, LLC | 8 | injection, powder, for solution | Generic drugs (ANDA) | November 30, 2021 |
| Avenacy, LLC | 7 | injection, powder, for solution | Generic drugs (ANDA) | September 1, 2025 |
| Bryant Ranch Prepack | 7 | tablet, film coated | Generic drugs (ANDA) | March 1, 2017 |
| Chartwell RX, LLC | 7 | powder, for suspension; tablet | Generic drugs (ANDA) | March 22, 2005 |
| Fresenius Kabi USA, LLC | 7 | injection, powder, lyophilized, for solution; injection, powder, for solution | Generic drugs (ANDA) | March 20, 2023 |
| Proficient Rx LP | 7 | tablet, film coated; powder, for suspension | Generic drugs (ANDA) | May 1, 2020 |
| Aurobindo Pharma Limited | 6 | tablet, film coated; powder, for suspension | Generic drugs (ANDA) | January 20, 2012 |
| Meitheal Pharmaceuticals Inc. | 6 | injection, powder, for solution | Generic drugs (ANDA) | November 27, 2006 |
| NorthStar Rx LLC | 6 | tablet, film coated; powder, for suspension | Generic drugs (ANDA) | January 20, 2012 |
| Onesource Specialty Pharma Limited | 6 | injection, powder, for solution | Generic drugs (ANDA) | May 1, 2025 |
| USAntibiotics, LLC | 6 | for suspension; tablet, coated | Authorized generics (NDA) | December 15, 2025 |
| Armas Pharmaceuticals Inc. | 5 | injection, powder, for solution | Generic drugs (ANDA) | May 1, 2025 |
| Bryant Ranch Prepack | 5 | tablet, film coated | Generic drugs (ANDA) | March 1, 2017 |
| Civica, Inc. | 5 | injection, powder, for solution | Generic drugs (ANDA) | September 8, 2025 |
| Devatis, Inc. | 5 | powder, for suspension; tablet, film coated | Generic drugs (ANDA) | November 1, 2024 |
| Provepharm Inc. | 5 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 11, 2023 |
| Teva Pharmaceuticals USA, Inc. | 5 | powder, for suspension; tablet, film coated | Generic drugs (ANDA) | January 13, 2005 |
| Apotex Corp. | 4 | injection, powder, for solution; injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 26, 2023 |
| Hikma Pharmaceuticals USA Inc. | 4 | powder, for suspension; tablet | Generic drugs (ANDA) | August 23, 2016 |
| Hospira, Inc. | 4 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 14, 2016 |
| Proficient Rx LP | 4 | powder, for suspension; tablet, film coated | Generic drugs (ANDA) | November 21, 2022 |
| Sagent Pharmaceuticals | 4 | injection, powder, for solution; injection, powder, lyophilized, for solution | Generic drugs (ANDA) | February 28, 2021 |
| Shandong Anxin Pharmaceutical Co., Ltd. | 4 | injection, powder, for solution; injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 14, 2023 |
| American Health Packaging | 3 | tablet, film coated | Generic drugs (ANDA) | July 26, 2024 |
| B. Braun Medical Inc. | 3 | injection, solution | New drug applications (NDA) | September 30, 2025 |
| Baxter Healthcare Corporation | 3 | injection, solution | New drug applications (NDA) | April 1, 2023 |
| BluePoint Laboratories | 3 | injection, powder, for solution | Generic drugs (ANDA) | August 11, 2021 |
| Direct_Rx | 3 | tablet, film coated; powder, for suspension | Generic drugs (ANDA) | August 1, 2025 |
| Hikma Pharmaceuticals USA Inc. | 3 | injection, powder, for solution | Generic drugs (ANDA) | December 22, 2009 |
| Micro Labs Limited | 3 | tablet, film coated | Generic drugs (ANDA) | March 1, 2017 |
| NorthStar RxLLC | 3 | injection, powder, for solution | Generic drugs (ANDA) | March 1, 2024 |
| Roerig | 3 | injection, powder, for solution | New drug applications (NDA) | November 22, 1991 |
| Wyeth Pharmaceuticals LLC, a Subsidiary of Pfizer Inc. | 3 | injection, solution | New drug applications (NDA) | March 1, 1998 |
| Advanced Rx of Tennessee, LLC | 2 | tablet, film coated | Generic drugs (ANDA) | March 3, 2023 |
| Aurobindo Pharma Limited | 2 | powder, for suspension | Generic drugs (ANDA) | April 19, 2019 |
| Bryant Ranch Prepack | 2 | tablet, film coated | Generic drugs (ANDA) | January 20, 2012 |
| Coupler LLC | 2 | tablet, film coated | Generic drugs (ANDA) | May 7, 2026 |
| Hawaii Repack, Inc. | 2 | powder, for suspension | Generic drugs (ANDA) | December 20, 2011 |
| Medsource Pharmaceuticals | 2 | tablet, film coated | Generic drugs (ANDA) | March 1, 2017 |
| Milla Pharmaceuticals Inc. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 11, 2023 |
| Northwind Health Company, LLC | 2 | tablet, film coated | Generic drugs (ANDA) | October 17, 2024 |
| PD-Rx Pharmaceuticals, Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | October 31, 2002 |
| PD-Rx Pharmaceuticals, Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | October 31, 2002 |
| Redpharm Drug | 2 | for suspension; powder, for suspension | Authorized generics (NDA) | September 19, 2022 |
| AbbVie Inc. | 1 | powder, for solution | New drug applications (NDA) | February 7, 2025 |
| Allegis Holdings, LLC | 1 | for suspension | New drug applications (NDA) | September 1, 2023 |
| Allergan, Inc. | 1 | powder, for solution | New drug applications (NDA) | December 26, 2014 |
| Cipla USA Inc. | 1 | suspension | Generic drugs (ANDA) | October 28, 2024 |
| Medical Purchasing Solutions, LLC | 1 | injection, powder, for solution | Generic drugs (ANDA) | February 10, 2012 |
| Melinta Therapeutics, LLC | 1 | injection, powder, for solution | New drug applications (NDA) | October 2, 2017 |
| Merck Sharp & Dohme LLC | 1 | injection, powder, for solution | New drug applications (NDA) | January 6, 2020 |
| Merck Sharp & Dohme LLC | 1 | injection, powder, lyophilized, for solution | New drug applications (NDA) | December 19, 2014 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 113 | 33.7% |
| Injection, powder, for solution | 81 | 24.2% |
| Powder, for suspension | 55 | 16.4% |
| Injection, powder, lyophilized, for solution | 38 | 11.3% |
| Tablet | 13 | 3.9% |
| Injection, solution | 9 | 2.7% |
| For suspension | 7 | 2.1% |
| Suspension | 7 | 2.1% |
| Tablet, coated | 5 | 1.5% |
| Tablet, multilayer, extended release | 2 | 0.6% |
| Powder, for solution | 2 | 0.6% |
| Tablet, chewable | 2 | 0.6% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.